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A 54-year-old woman from Texas sought a second medical opinion 6
years ago at the Brigham and Women's Hospital in Boston because of
concern about her family history of renal disease. In 1978, her creati-
nine clearance (Ccr) was reported to be 56 mI/mm and her blood
pressure 170/100mm Hg. She had been told by her family physician that
she had hypertension and chronic renal failure and had been given a
thiazide diuretic. She has an extensive family history of nephritis
involving at least 4 generations (Fig. I).
Between 1978 and 1984, her physician treated her for urinary
infections and hypertension. In 1981, her Ccr was 42 mI/mm. In 1983,
she had a urinary infection with pyuria; her Ccr was 30 mI/mm and a
hearing test was "normal." In the fall of 1984, she was referred to a
nephrologist who noted hypertension and edema. Measurement of
glomerular filtration rate (GFR) by 25I-iothalamate renal clearance
disclosed a value of 20.7 mI/mm; propranolol and a thiazide diuretic
were prescribed. She came to me for another opinion; since then she
has been followed annually, and every 4 to 8 weeks by the referring
nephrologist.
In October 1984, I found the patient to be a well-nourished woman in
no acute distress except for understandable concern about her progno-
sis for familial renal disease (Fig. I). She had not had a renal biopsy, but
renal biopsy of others in the family had shown an interstitial nephritis;
none of the family members had any hearing disorder. A review of
systems revealed hypertension but no hearing impairment. She had no
symptoms suggesting cardiopulmonary disease except for mild fatigue
on exercising, but she did complain of intermittent constipation. Uri-
nary symptoms included bouts of frequency and urgency occurring
about two times a year that had been diagnosed as urinary tract
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infections. She also had noted swelling of her ankles, especially after
sitting for long periods.
Physical examination revealed a slender, pleasant woman who was
well informed about the consequence of renal failure. She weighed 55.5
kg and her blood pressure was 200/98 mm Hg. Her pulse was 86
beats/mm; respirations, 16/mm; and she had no skin lesions. The
physical examination was unremarkable except for I + pedal edema
bilaterally. Serum biochemistry values were: urea nitrogen, 59 mg/dl;
serum creatinine, 2.9 mg/dl; bicarbonate, 27 mEq/liter; potassium, 4.1
mEq/liter; calcium, 9 mgfdl; phosphorus, 4.8 mg/dl; uric acid, 7.4 mg/dI;
alkaline phosphatase, 67 U/liter; triglycerides, 131 mg/dl; and choles-
terol, 231 mg/dI. Her hematocrit was 36%, and the white count and
platelet count were normal. Urinalysis showed 1+ protein and 8—10
erythrocytes/high-power field, but no leukocytes or casts.
The purpose of a restricted diet was discussed with the patient and
her husband, and she decided to begin this therapy. She was evaluated
by a dietician who judged her usual intake to include more than 60 g of
protein/day (>1 g/kg/day); she was instructed how to calculate the
protein content of foods. She was given diet plans for a 25 g/day protein
(mixed-quality) and 30 kcal/kg/day diet. Her medications included
Aminess, 5 tablets 3 times daily; calcium carbonate, 3.75 g/day;
B-vitamin complex, 1 tablet daily; furosemide, 80 mg/day; and atenolol,
50 mg/day. Over the past 6 years, she has been in regular contact with
a dietician.
During these 6 years, the patient has been treated for hypertension
with several types of drugs, including an angiotensin-converting-en-
zyme inhibitor, different beta-blockers, and calcium-channel blockers.
She has had two bouts of severe diarrhea with dehydration and was
hospitalized on one occasion for administration of intravenous antibi-
otics. Radiologic evaluation led to a diagnosis of diverticulosis. Other-
wise, she has had no symptoms attributable to renal failure. Her current
weight is 56.8 kg. She walks about I mile daily and works as a church
administrator. Serial estimates of her protein intake were calculated
from 24-hour urine specimens for urea nitrogen content using the
relationships described by Maroni et al [1]. Urea nitrogen excretion
averaged 4.8 g N/day, with a coefficient of variation of 17% (N = 44).
Renal function was analyzed by measuring serum creatinine, creatinine
clearance, and '25l-iothalamate clearance. Values of serum creatinine,
GFR, and estimated protein intake (uncorrected for the essential amino
acid supplements) during the past 6 years are shown in Fig. 2.
Discussion
DR. WILLIAM E. MITCH (Director, Renal Division, and E.
Garland Herndon Professor of Medicine, Emory University
School of Medicine, Atlanta, Georgia): Early studies revealing
that patients with chronic renal failure and severe uremia
improved symptomatically when dietary protein was restricted
became the initial rationale for dietary therapy [2, 3]. In some
as-yet-unidentified way, the accumulation of nitrogenous waste
products and inorganic ions causes the clinical and metabolic
disturbances characteristic of uremia. Dietary protein restric-
tion has been used as therapy because excess dietary protein (in
contrast to carbohydrate and fat) is not stored but is degraded to
urea and other waste products, which accumulate in patients
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Fig. 1. Clinical observations in 58 members (4 generations) of a family with a hereditary form of renal disease. The disease is inherited in an
autosomal dominant fashion. The patient (proband) has intermittent microscopic hematuria and chronic renal failure.
with impaired renal function. Protein restriction also helps
control the accumulation of sodium, potassium, phosphates,
and other ions normally excreted by the kidney because foods
rich in protein contain large amounts of these ions as well. The
difficulty in implementing dietary protein restriction therapy is
that an inadequate protein intake results in net degradation of
endogenous protein stores, which contributes to the loss of lean
body mass observed in severely uremic subjects treated with
excessively restricted diets [4].
As the patient discussed demonstrates, it is possible to avoid
this complication; the treatment she has followed for 6 years
yields a protein intake equivalent to about 38 glday. Her weight
has remained stable; she continues to work and exercise
regularly. She has overcome bouts of diverticulitis on two
occasions. Stabilization of her residual renal function over this
same 6-year period (Fig. 2) also raises the possibility that
dietary protein restriction might slow the rate of loss of renal
function, even in patients with inherited forms of renal disease.
Prospective trials currently are underway in Europe, Japan, and
the United States to test this exciting but unproved possibility.
I will discuss the principles underlying the implementation of
a low-protein diet in patients with chronic renal failure and will
place special emphasis on factors affecting nutritional status. I
also will address the evidence that dietary manipulation can
influence the course of renal insufficiency.
Urea and protein intake
No single toxin has been identified that can account for the
spectrum of abnormalities found in uremia. Urea has been the
most widely studied because the BUN concentration is related
to the severity of uremia. This relationship was underscored
when the National Cooperative Dialysis Study reported that
maintaining the average BUN close to 50 mg/dl was associated
with fewer complications than was maintaining the average
BUN approximately 90 mg/dl by less-intensive dialysis [5].
Johnson et al tested the toxicity of urea by adding it to the
dialysis bath of otherwise "well-dialyzed" patients [6]. They
found that raising the BUN to about 140 mg/dl for more than
one week reproduced uremic symptoms. On the other hand, a
moderately high BUN causes few symptoms when renal func-
tion is otherwise normal. Patients with defects in their ability to
excrete urea who have moderate azotemia even though their
GFR is normal do not have uremic symptoms [7], nor did a
woman who ate enormous quantities of fishmeal protein and
maintained a BUN above 65 mg/dl for at least 3 years [8].
Regardless of whether urea per se is toxic, the rate of urea
Proband
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production is directly related to the amount of protein eaten
(Fig. 3). Hence, the BUN concentration is related to protein
intake, provided urea clearance is stable. This relationship
arises because urea is synthesized using nitrogen derived from
amino acid catabolism. The only suggestion that urea metabo-
lism is abnormal in uremic subjects is that some patients have a
mildly high arterial ammonia level [9].
Urea has three fates: it is excreted by the kidney, accumu-
lates in body water, or is metabolized to ammonia plus carbon
dioxide by gastrointestinal bacteria. In the last case, the ammo-
nia is recycled to urea in the liver. Consequently, there is no net
loss of nitrogen or urea [10]. The difference between urea
produced and recycled is termed "urea nitrogen appearance"
(UNA); it is the urea that "appears" in urine and body water.
The UNA is physiologically important because it closely cor-
relates with the amount of nitrogen (and therefore protein)
eaten [1, 11]. Fortunately, UNA can be measured easily.
To measure UNA, the average daily urea nitrogen excretion
first must be determined. Since urea excretion is not constant
throughout the day, shorter collections will not suffice. The
second step is calculating the average change in the urea pool.
This calculation is relatively simple because the urea space is
equal to body water, assumed to be 60% of body weight in
nonedematous patients [1, 12]. Because urea distributes equally
throughout body water, the average change in the pool can be
calculated from changes in BUN and weight measured over 5
days [101. To calculate UNA, the daily rate of change in the
urea poo1 (either positive or negative) is added to the average
rate of urea excretion measured over 3 days. Obviously, if the
BUN and weight are stable (that is, the patient is in a steady
state), the UNA is equal to urea nitrogen excretion. Calculation
of UNA assumes that short-term variations in body weight
reflect only changes in body-water content.
Calculation of UNA can be used in a least three ways to
assess dietary therapy of patients with chronic renal failure.
The assessments are based on the principle of conservation of
mass and the following relationship: BN = 'N — [UNA + 0.031
gN/kglday]. First, when nitrogen intake (IN) is known, nitrogen
balance (BN) can be estimated accurately because nonurea
nitrogen (NUN) excretion does not vary substantially with
protein intake (Table 1). The average value of NUN is 0.031
gN/kg/day (Fig. 4) [1]. Thus, nitrogen intake (16% of protein
intake) minus the sum of UNA plus the product of 0.031 gN/kg
and body weight gives an estimate of BN (Table I). In 19
non-dialyzed patients with chronic renal failure consuming 34 to
94 grams of protein/day, BN estimated by this method did not
differ statistically from values obtained by actual measurement
of BN [1]. Second, ifBN is assumed to be zero, protein intake
can be estimated from UNA using the same relationship (Table
1). When the estimated and prescribed intakes differ by more
than 20%, investigation for occult gastrointestinal bleeding or
an unrecognized catabolic illness is indicated; or, intensive
dietary counseling might be needed. Third, if urea clearance is
known, the steady-state BUN expected for a prescribed protein
intake can be calculated: if the quotient of UNA in gN/day
divided by urea clearance in liters/day is multiplied by 100, the
answer is the steady-state BUN in mg/dl (Table 1). Note that in
the third example, the steady-state BUN is being calculated
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Table 1. Relationships among protein intake, nitrogen balance, and
steady-state BUN
If the protein intake of a 70 kg patient is 50 g/day and the steady-
state urea excretion (UNA) is 10.3 gN/day, then:
BN = 'N - (UNA + NUN)
BN = 12.8 — [10.3 + (0.31 x 70)]
BN = 0
U riflery
urea
If nitrogen balance is assumed to be zero, then intake can be
estimated:
BN = 'N - UNA - NUN
'N = UNA + (0.31 gN/kglday x weight)
-
0
'S 0
I I I I I I
0
If a 70 kg patient has a urea clearance of 8.6 liters/day (6 mllmin),
then the steady-state BUN is estimated as:
(IN — 0.031 gN/kg)
steady-state BUN = ,, X 100( urea)
Abbreviations: BN, nitrogen balance (gN/day); 'N' nitrogen intake
(gN/day); UNA, urea nitrogen appearance rate (gN/day); BUN, blood0 urea nitrogen concentration (mg/dl); Curea, urea clearance (liters/day).
Nitrogen balance
oQ-4----0 Using estimates of UNA and NUN to evaluate nitrogen
metabolism has limitations. First, incomplete urine collection
I , can limit the precision of calculations based on UNA. The only
14 12 10 8 6 4 2 0 way to reduce this error is to collect urine for 3 days and obtain
Nitrogen intake, g/day
Fig. 3. Nitrogen balance and urinary urea as a function of nitrogen
intake in patients with chronic uremia fed varying quantities of dietary
protein. Subjects fed less than 4 g nitrogen/day were in neutral or
negative balance. When the diet contained more than 4 g nitrogen/day,
balance was slightly positive, but the increment in intake was equal to
the increment in urinary urea nitrogen. (From Ref. II).
(thus BUN and weight must be stable), so UNA is equal to urea
excretion.
I emphasize these concepts because of their practical utility
and because I want to clarify some confusing terminology.
Similar concepts were used by Sargent et al to describe urea
generation (Ga) and the protein catabolic rate (PCR) [13]. In
dialysis patients as well as nondialysis patients, the nitrogen for
urea synthesis is derived from amino acid degradation. In short,
net urea production (or G) in dialysis patients is the same as
UNA. Because G and UNA are calculated from the same
variables, they both closely parallel nitrogen (and therefore
protein) intake. The more confusing term, PCR, is simply the
protein equivalent of the UNA plus a constant for non-urea
nitrogen excretion of 1.7 gN/day. As I said, PCR closely
approximates protein intake in patients who are in nearly zero
nitrogen balance (BN). Clearly, PCR does not measure protein
catabolism because the daily turnover of protein in humans is
far greater than protein intake (and hence, PCR). Results of
isotope dilution studies place both the rate of protein synthesis
and of degradation at 45—55 gN/day [14], roughly equivalent to
the protein in 1.0 to 1.5 kg muscle. Although the principle of
conservation of mass dictates that the difference between
"whole-body" protein synthesis and degradation must equal
waste nitrogen production x 6.25, the implication that PCR
yields insight into, or is a measure of, whole-body protein
catabolism is erroneous.
an average value. Second, urea clearance varies during the day.
This variation could explain why several days are required for
normal subjects to reach a new steady-state of urea excretion
following a change in diet [14]. In patients with renal damage,
urea clearance may vary less during the day, but more time will
be required to achieve a new steady state with stable BUN and
weight. These factors make it imperative to include an estimate
of the change in accumulated urea when assessing UNA in
patients with renal insufficiency; for normal subjects, estimating
changes in accumulated urea is not critical because of the 7- to
8-hour half-life of urea. Even in normal subjects, changes in the
size of the pool do not fully explain the delay in achieving a
steady state following changes in dietary protein. Perhaps
differences in protein utilization (and hence, waste nitrogen
production) occur in the presence of large day-to-day changes
in dietary protein.
Third, proteinuria can affect accurate measurement of nitro-
gen metabolism. The 0.031 gN/kg/day value for non-urea nitro-
gen excretion was derived from patients with urinary protein
excretion less than 5 g/day (Fig. 4). If proteinuria exceeds 5
glday, the extra nitrogen lost must be added to the NUN value.
Evidence indicates that proteinuria affects protein balance.
Kaysen and associates showed that in nephrotic rats, protein-
uria decreased lean body mass, and raising dietary protein
exacerbated proteinuria [15]. In humans, the same group of
investigators showed that reducing dietary protein to 0.8 g/kg
body wt/day from 1.6 g/kg/day resulted in less proteinuria
without compromising albumin homeostasis [16]. Even though
a protein-restricted diet can spare albumin stores, its effect on
body protein stores is less clear, especially during long-term
therapy.
The protein requirement, defined as the minimum amount of
protein that balances obligatory nitrogen losses while maintain-
ing energy equilibrium and permitting modest physical activity,
can be divided into two components: total nitrogen and essen-
z
E
Fig. 4. Calculated values of total non-urea
nitrogen excretion (NUN) in normal subjects
(A, •, U), and patients with chronic renal
failure being treated with nutritional therapy
(•, ®. ®,®) by dialysis (•, ti), or CAPD2 4 6 8 10 12 14 16 18 20 l). The average value found in the study
Nitrogen intake by Maroni et at was 0.031 g nitrogen/kg/day
gN/day (©). (From Ref. 1.)
tial amino acids (EAA). From these considerations, a pre-
scribed diet may be deficient in protein quantity, quality (that is,
the amount of EAA), or both. Despite its limitations, nitrogen
balance (BN) remains the "gold standard" for assessing dietary
protein requirements [14]. To measure BN, the difference in
nitrogen in the diet and that in urine and stool plus an "allow-
ance" (for example, 0.5 gN/day to account for minor losses
from sweat, desquamated skin, or hair) is obtained. For uremic
patients, the urea pool also must be taken into account.
When defining nitrogen requirements, one must specify an
adequate energy intake, because for any given protein intake,
BN improves when calories are increased [17]. It is important
that we understand how current protein recommendations were
established: they are based on interpolation of several measure-
ments of BN in individuals to identify the level of dietary protein
that should produce zero BN for groups of subjects. Because
the recommended intake for all subjects is based on extrapola-
tion of data from individuals, the recommended intake doesn't
always apply to groups of patients differing in age, degrees of
activity, etc.; clearly the protein required by an individual could
vary substantially from the minimum value. For these reasons
the Food and Agriculture Organization/World Health Organi-
zation/United Nations University (FAO/WHO/UNU) "expert
group" introduced the concept of a safe intake level [17]. This
safe level is defined as the average requirement plus two
standard deviations, a value that should meet the protein
requirements of all but 2.5% of individuals.
Serum albumin and transferrin levels are used extensively to
assess nutritional status [18]. Experience with other serum
proteins is too limited to recommend their use. When using
serum albumin, one should recognize that its concentration is
determined by many factors, including the synthesis, catabo-
lism, and excretion of albumin; changes in plasma volume; and
distribution between extracellular and intravascular spaces. In
malnourished nonuremic subjects, as well as in chronically
uremic and nephrotic patients, both albumin synthesis and
catabolism can be decreased; in addition, evidence suggests
that albumin shifts into the intravascular compartment [16, 18,
19]. Clearly, the plasma albumin concentration need not accu-
rately reflect total albumin mass under these circumstances.
Serum transferrin is another indicator of malnutrition; it has
a shorter half-life than albumin (about 8 days versus 20 days for
albumin). However, transferrin concentration, like albumin,
varies with hydration and protein turnover but also changes in
the presence of inflammation and/or changes in iron stores [18,
20].
Besides measurements of BN and serum proteins, anthropo-
metrics (weight, mid-arm muscle circumference, triceps skin-
fold thickness) are commonly used to estimate body composi-
tion and nutritional adequacy [18]. Reproducibility depends on
the skill of the observer, the number of sites examined, the use
of the dominant or non-dominant arm, and the degree of
hydration (for example, in dialysis patients). Unfortunately,
many of the values used as standards were obtained from
studies in underdeveloped countries, where the health of the
study population was not defined and may not represent a
standard for normal values. Also, the influences of age and
socioeconomic status have not been evaluated. Finally, virtu-
ally no data have examined how closely subnormal anthropo-
metric values relate to an adverse clinical outcome. Thus, serial
anthropometric measurements in the same individual are more
likely to provide useful information.
The concentrations of plasma amino acids also have been
used to assess nutritional status [20]. But the amino acid pattern
generally reflects the disease process, recent changes in protein
intake, or both, and is a less sensitive indicator of body
composition than are serum proteins and anthropometrics. On
the other hand, measurements of plasma amino acids have
revealed abnormalities that seem to be characteristic of uremia.
For example, the tyrosine level is low because uremia limits the
activity of the enzyme converting phenylalanine to tyrosine
[20]. Also, metabolic acidosis activates skeletal muscle
branched-chain amino acid dehydrogenase, the rate-limiting
enzyme regulating breakdown of these amino acids [21, 221. In
fact, the subnormal levels of branched-chain amino acids
present in rats with chronic renal failure could be attributed to
metabolic acidosis [21]. Recent data from Bergstrom and asso-
ciates suggest a similar adverse effect of acidosis in humans;
these authors documented a close correlation between serum
bicarbonate and the concentration of valine in muscle of dialy-
sis patients [231. Plasma amino acid levels might provide insight
into methods of improving nutrition. Alvestrand et al studied
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Abnormal energy metabolism Acidosis
4 Protein degradation
Loss of lean body mass
Increased EAA and nitrogen requirements
predialysis patients fed 16 to 20 g of protein plus a supplement
of EAA in proportions designed to correct abnormalities in
amino acid concentrations [24]. The regimen substantially cor-
rected intracellular amino acid concentrations and improved
BN.
Protein conservation in chronic uremia
In rats with chronic renal failure, abnormalities in protein
metabolism include increased protein and amino acid degrada-
tion and impaired insulin-stimulated protein synthesis in muscle
(Fig. 5) [25]. The catabolic effects of uremia are accentuated by
fasting [26]. To date, the only factor in uremia shown to impair
protein metabolism is metabolic acidosis. Even mild metabolic
acidosis (serum bicarbonate less than 21 mM) can account for
accelerated catabolism of protein and branched-chain amino
acids in muscle of rats with chronic renal failure. Both catabolic
processes were fully corrected when sodium bicarbonate was
added to the diet [20, 25]. The same adverse effects of acidosis
are present in humans with chronic renal failure; sodium
bicarbonate decreases urea production and improves BN in
these patients [27]. As I noted, evidence indicates that acidosis
changes branched-chain amino acid metabolism in muscle of
patients with chronic renal failure [23]. Together these results
suggest that the metabolic acidosis of chronic renal failure
increases nitrogen requirements and could counteract adaptive
responses to a low-protein diet.
Energy metabolism also influences protein metabolism in
chronic renal failure (Fig. 5). In rats with chronic renal failure,
adiposity is subnormal and inversely correlates with body
weight and muscle protein turnover [26]. Besides the evidence
that insulin-mediated glucose metabolism is abnormal in ure-
mia, muscle lactate production correlates highly with protein
turnover [27].
The metabolic responses that permit adaptation to a protein-
restricted diet were identified only recently. The problems of
assessing "whole-body" protein synthesis and degradation and
interpreting how changes in these values are expressed in
specific tissues continue to perplex investigators. Moreover,
there are large voids in our understanding of factors controlling
protein metabolism [281.
Changes in whole-body protein metabolism have been exam-
ined by analysis of the turnover of infused amino acids. The
Fig. 5. Factors causing loss of lean body mass and
increased essential amino acid (EAA) and nitrogen
requirements in uremia. Results from experimental
animals with renal insufficiency indicate that both
abnormal energy metabolism and metabolic acidosis
compromise nitrogen metabolism; there is also
evidence that an unidentified factor in uremia limits
the capacity for protein synthesis.
technique requires a constant infusion of a labeled amino acid
and collection of expired carbon dioxide to allow calculation of
rates of protein synthesis and breakdown as well as amino acid
catabolism [29]. Normal subjects primarily respond to a sharp
change in dietary protein by varying amino acid oxidation.
When protein intake is below the minimum requirement, how-
ever, additional responses are activated, including a decrease
both in protein synthesis and degradation [30, 31]. Slowing of
protein turnover blunts the adverse effects of an inadequate diet
on protein stores but it does not prevent loss of body protein.
The importance of understanding protein nutrition is that aci-
dosis in uremia could increase amino acid oxidation and protein
breakdown and thus limit a patient's capacity to successfully
adapt to a low-protein diet.
Information about how patients with chronic renal failure
adapt to a low-protein diet is limited. Goodship and colleagues
used the amino acid infusion technique in patients whose
average serum creatinine was 5 mg/dl and in normal subjects.
Both groups were fed two levels of protein, 1.0 and 0.6 g
protein/kg/day [29]. They tested the subjects' capacity to adapt
to the minimum protein intake (0.6 g/kg/day) by measuring
whole-body amino acid oxidation and protein synthesis and
degradation; they also measured BN. The authors reached two
important conclusions: (1) The metabolic responses to the
low-protein diet of patients with chronic renal failure and
normal subjects were indistinguishable. Both groups had re-
duced amino acid oxidation and protein degradation; protein
synthesis changed minimally with the low-protein diet. How-
ever, none of the patients was acidotic, so more severely
uremic (or acidotic) patients might have different responses
from normal subjects. For example, acidosis could stimulate
protein breakdown and reduce the efficiency of using dietary
protein by stimulating essential amino acid catabolism. (2) The
normal subjects and the patients were in negative BN during the
first week of the low-protein diet (Fig. 6). This response could
not be explained by a low energy intake or by changes in the
urea pool (the latter was measured). It is interesting that the
nitrogen balance occurring with a low-protein diet was dis-
tinctly different from that of the patients fed even less protein
but given a supplement of ketoacids [32]. In patients fed this
regimen, BN was zero.
+ Protein synthesis
4 Amino acid oxidation
Fig. 6. Nitrogen balances measured using
classical and isotopic methods in patients
with chronic renal failure (CR1) and in normal
subjects fed I g protein/kg/day (HP) and 0.6 g
protein/kg/day (LP). Isotopic nitrogen balance
was calculated from rates of protein synthesis
and degradation measured during infusion of
L-[ l-C] leucine and extrapolated to
represent rates over 24 hours. The difference
is the nitrogen balance during the HP period
minus that in the LP period for CR1 patients
and normal subjects. The difference in
measured or calculated nitrogen balances was
the same for both groups of subjects. (From
Ref. 29.)
Dietary protein requirements in uremia
More than 25 years ago, studies suggested that patients with
advanced chronic renal failure could maintain BN while con-
suming very low amounts of protein (about 4 SD below the
mean requirement for normal subjects) [2, 3]. Giordano postu-
lated that nitrogen derived from urea degradation could be used
to synthesize amino acids and ultimately protein [2]. Tests of
this hypothesis in patients with chronic renal failure have failed
to confirm that urea reutilization contributes significantly to
protein nutrition. For example, only 2% to 6% of the nitrogen in
albumin from patients with chronic renal failure was derived
from urea degradation [33]. Furthermore, when we suppressed
urea degradation by administering nonabsorbable aminoglyco-
side antibiotics orally, analysis of urea kinetics showed that
ammonia derived from urea degradation was simply recycled to
urea [10] and BN actually improved [34]. Clearly, if ammonia
arising from urea degradation is an important source of nitrogen
for amino acid synthesis, BN should have become negative
when urea degradation was inhibited. We concluded that urea
degradation does not contribute substantially to nutrition in
patients with chronic renal failure.
The FAO/WHO/UNU expert group concluded that the aver-
age protein requirement for normal subjects is about 0.6 g
protein/kg/day [17]. It is now recognized that predialysis pa-
tients require about the same amount as normal subjects. To
ensure an adequate intake of EAA, approximately two-thirds of
the protein should be of "high biologic value" (for example,
eggs or lean meat) and calories must be sufficient to meet energy
requirements [35]. These recommendations are emphasized
because of reports that this level of protein is associated with
negative BN, at least during the first week of adaptation to the
diet [291.
More severe protein limitation than the minimum require-
ment of 0.6 g protein/kg/day is ill advised because EAA intake
would be insufficient to maintain BN. An acceptable alternative
is further limitation of protein (about 20 glday) and the addition
of a supplement of EAA or their nitrogen-free analogues
(ketoacids). This strategy actually could increase the variety of
foods and improve compliance because all protein does not
have to be of the "high-quality" type. Generally, a regimen of
15 to 25 g/day of unrestricted quality protein plus EAA provided
in capsules or tablets promptly corrects uremic symptoms while
promoting neutral BN and muscular strength and maintaining
serum albumin and transferrin [24]. In another study, serum
albumin and transferrin were maintained and lean body mass
increased or remained stable as long as no intercurrent illnesses
prevented an adequate caloric intake [36].
Essential amino acids usually are provided in the proportions
recommended for normal subjects. It is likely, however, that
these proportions are not optimal for patients with chronic renal
failure, because plasma and intracellular concentrations of
amino acids in uremic patients differ markedly from those in
normal subjects or normal subjects eating a low-protein diet
[20].
A newer EAA supplement (Aminess-Novum, KabiVitrum)
contains tyrosine. Tyrosine's synthesis from phenylalanine is
reduced in uremic patients, and giving them tyrosine seems to
improve their nutrition [20]. Histidine is included in this new
supplement because these patients given a histidine-deficient
diet developed a syndrome characterized by malaise, an erythe-
matous scaling rash, and negative BN; supplemental histidine
rapidly corrected these abnormalities [20]. The new EAA
supplement also contains a higher proportion of valine. During
long-term therapy, intracellular amino acid concentrations im-
proved, as did BN [24]. These results strongly suggest that the
amino acid requirements of uremic subjects are different from
those of normal individuals.
Nitrogen intake also can be reduced by taking advantage of
the capacity of most tissues to convert the alpha keto analogues
of seven EAA (ketoacids) to EAA. Ketoacids of the two
remaining EAA, lysine and threonine, are not transaminated,
and these amino acids must be provided. Proof that a mixture of
ketoacids could replace their respective amino acids in the diet
of patients with chronic renal failure was provided by showing
that BN was zero over periods of 5 to 7 days even when patients
were eating a virtually protein-free (and hence, EAA-free) diet
[37].
In early studies, ketoacids were provided to uremic patients
as calcium salts [20]. Gastrointestinal distress was an occa-
sional problem, and about 5% of patients developed hypercal-
cemia during long-term therapy, although the latter was rarely
clinically significant. A new supplement was designed to avoid
the problems associated with calcium salts while providing a
more optimal proportion of ketoacids and amino acids for
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uremic patients [32]. Ketoacids of the branched-chain amino
acids are given as salts of basic amino acids (ornithine, lysine,
and histidine). Tyrosine, small amounts of threonine, and the
hydroxy analogue of methionine are added, but phenylalanine
and tryptophan are omitted because the diet contains enough of
these amino acids to achieve nitrogen balance [32].
A diet containing 20 to 25 g of mixed-quality protein plus this
mixture of ketoacids produced a zero BN and decreased UNA
in patients with severe chronic renal failure (average GFR, 4.8
ml/min) [32]. Weight and serum albumin and transferrin levels
were maintained over periods ranging from 4 to 19 months [32].
These results are particularly interesting because the supple-
ment was "unbalanced"; that is, it lacked certain EAA or EAA
analogues. It is important that neither the ketoacid nor an EAA
supplement has any detectable nutritional benefit in uremic
subjects eating more than 40 g/day of predominantly high-
quality protein, presumably because the excess EAA or ana-
logues are metabolized [201.
Lucas et al suggested that a ketoacid regimen can reduce lean
body mass [191. They treated 12 patients with only 0.2 g
protein/kg/day (versus approximately 0.3 g/kg in other studies)
and with approximately 50% of the amount of ketoacids used by
others [20, 32]. Therapy was associated with a decrease in
symptoms as well as a decrease in BUN, serum phosphate,
parathyroid hormone, and the calcium-phosphorus product.
Despite stable serum albumin and transferrin levels, the body
weight, creatinine excretion, and mid-arm muscle circumfer-
ence decreased significantly, suggesting loss of lean body mass.
This study emphasizes the importance of providing a sufficient
intake of protein and ketoacids (and possibly energy); it also
points out the hazards of monitoring changes in plasma proteins
as the sole index of nutritional status.
A possible anabolic effect of ketoacids is supported by
studies suggesting that alpha ketoisocaproate (the ketoacid of
leucine) improves protein conservation. In-vitro studies using
rat muscle show that alpha ketoisocaproate reduced protein
degradation [38]. Evidence also points to an anticatabolic effect
in humans. Infusion of alpha ketoisocaproate into starving,
obese adults with normal renal function decreased urea nitrogen
production, whereas an equimolar infusion of leucine did not
change BN [39]. The clinical relevance of alpha ketoisocaproate
to dietary therapy is presently unclear, and further investigation
is warranted.
A ketoacid regimen also might improve clinical and biochem-
ical evidence of secondary hyperparathyroidism. For example,
ketoacid therapy treatment has been associated with decreased
serum phosphate, alkaline phosphatase, and parathyroid hor-
mone, as well as with increased serum calcium and improve-
ment in renal osteodystrophy [20]. Serum levels of I ,25-dihy-
droxy-cholecalciferot increased, whereas serum concentrations
of 25-hydroxy-cholecalciferol and calcitonin did not change
[20]. Although the improvement in divalent ion metabolism is
likely due in part to the concomitant reduction in dietary
phosphorus associated with this regimen, suppression of phos-
phate absorption also might contribute; calcium salts of ketoac-
ids appear to be at least as effective as calcium carbonate in
binding phosphorus [20].
Improvement in metabolic acidosis is an obvious conse-
quence of the reduction in hydrogen ion produced during
metabolism of dietary phosphate and sulfur-containing amino
acids. Lessening the catabolic influence of acidosis might
partially explain the beneficial effect of restricted diets on
protein metabolism in renal failure [21, 25, 27]. In summary,
long-term treatment of patients with severe renal insufficiency
with a very-low-protein diet supplemented with EAA or ketoac-
ids maintains nutrition while reducing uremic symptoms, sec-
ondary hyperparathyroidism, and metabolic acidosis.
High-protein diets have been used for nephrotic patients but,
in view of recent reports, the appropriateness of this maneuver
is questionable [161. When albumin turnover and excretion
were measured in 9 nephrotic subjects fed a high- (1.6 g/kg/day)
and low- (0.8 g/kg/day) protein diet containing 35 kcal/kg/day
for 10 to 14 days, the more restrictive diet was associated with
a significant reduction in albumin excretion (mean, —2.74 g/day;
range, —0.1 to —7.4 g/day) and with a small increase in serum
albumin (+0.2 g/dl). Although albumin synthesis was lower
with the 0.8 g/kg/day diet, this decrease was more than com-
pensated for by decreases in albumin catabolism and fractional
excretion. Albumin synthesis did increase significantly on the
high-protein diet but was offset by increased proteinuria. In
spite of these encouraging results, simultaneous measurements
of BN and other nutritional indices are needed to assess body
protein stores before protein-restricted diets can be recom-
mended for all nephrotic patients. Moreover, protein-depleted
subjects and children might require more dietary protein.
Energy requirements in uremia
The energy requirement is defined as the calories needed to
maintain health and normal physical activity. Because inade-
quate calories, defective energy metabolism, or both could raise
protein requirements and aggravate uremia, successful therapy
requires that caloric intake be adequate. Unfortunately, little is
known about factors influencing energy requirements or the
complex relationship between caloric intake and maintenance
of protein stores.
The FAO/WHO/UNU recommendations for energy intakes
were determined from approximately 11,000 basal metabolic
rates in healthy individuals of both sexes and all ages. Although
these recommendations are considered the best available, it
should be recognized that as much as 50% of the variability in
energy requirements must be attributed to factors other than
age, gender, and weight [17]. With regard to designing a diet for
a uremic patient, the precision of estimating the energy require-
ment depends heavily on the consistency and accuracy of
estimated time spent on various physical activities.
In patients with chronic renal failure, adaptation to inade-
quate caloric intake could involve changes in metabolism,
decreased physical activity, and/or loss of lean body mass (Fig.
5). In semi-starved subjects, the basal metabolic rate decreased
about 15% over 3 weeks; further adaptation reduced lean body
mass [17]. Well-nourished individuals can achieve energy bal-
ance with only one-half of their usual calories if physical
activity is limited, but lean body mass will diminish. Evidence
suggests that the range of caloric intake compatible with suc-
cessful adaptation is small [17].
Few studies have examined the caloric requirements of
patients with chronic renal failure or how they adapt to a
reduced caloric intake. Kopple et at varied the energy intake of
6 pre-dialysis patients between 15—45 kcallkg/day while keeping
protein intake at 0.55—0.60 g protein/kg/day. The authors con-
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cluded that 35 kcal/kg/day could adequately maintain BN [351.
The same group found that energy expenditure of predialysis
and hemodialyzed patients during rest and exercise did not
differ from that of control subjects [401. Thus, calorie require-
ments of stable patients with chronic renal failure, like protein
requirements, seem to be similar to those of normal subjects
[20].
Progression of chronic renal failure
Patients with established renal failure rarely recover; they
continue to lose renal function even when the disease process
that initially damaged the kidneys is no longer active [20]. In the
early 1970s, it was believed that the natural history of renal
insufficiency was unpredictable; the outcome of renal disease
usually was described as the percentage of patients surviving
until end-stage renal disease occurred or until a predetermined
level of serum creatinine was reached. In fact, the rate of loss of
renal function over time is constant in the majority of patients,
although its magnitude can vary widely among individuals with
the same disease. To what degree the severity of the underlying
disease process, other concomitant factors such as hyperten-
sion, or the method used to assess renal function contribute to
variability in rates of progression is unknown.
Accurate assessment of the natural history of progressive
renal insufficiency is useful both for prognosis and for deter-
mining whether therapy has altered the course of the underlying
disease. To evaluate the efficacy of a specific therapy and/or
factor(s) influencing the loss of residual renal function, two
questions must be asked: (1) How can residual renal function be
estimated; and (2) How can changes in renal function be
measured most precisely? These questions address different
tasks; the former determines renal function at one point in time,
whereas the latter examines how renal function changes during
the course of the illness.
The glomerular filtration rate has been estimated from serum
creatinine. However, a single value of serum creatinine is only
a crude estimate of the glomerular filtration rate; serum creat-
mine might not be elevated above the 95% confidence interval
of "normal" until the GFR has declined by at least 50% [411. As
Levey discussed in a recent Nephrology Forum devoted solely
to the issue of measurement of GFR, variability in creatinine
production and tubular secretion results in wide confidence
intervals for the relationship between serum creatinine and
inulin clearance [42]. As renal failure advances, creatinine
excretion decreases due to extrarenal creatinine clearance [43].
Extrarenal clearance was found to be relatively constant,
averaging 0.038 liter/kg/day; this finding indicates that as renal
function declines, extrarenal metabolism represents a progres-
sively greater proportion of total creatinine elimination. Several
factors influence creatinine production, so it is not surprising
that questions have arisen about its use as a measure of renal
function. There also is the problem of day-to-day variability in
24-hour creatinine clearances [44, 45]. These concerns limit the
use of serum creatinine and creatinine clearance as a measure-
ment of GFR and, by implication, the number of functioning
nephrons. Although this topic has been reviewed, the published
data comparing methods are scarce [41, 42, 44, 45].
One major problem in analyzing whether changes in diet alter
the progression of renal disease is determining the predictability
of repetitive measurements of renal function. The realization
that the decline is predictable and that it occurs at a constant
rate was first recognized in 1976, when it was reported that the
decline in the reciprocal of serum creatinine (Scr) over
periods averaging 71 months was linear in 31 of 34 patients [46].
Patients in this initial report had not had any dietary manipula-
tion. At least two lines of evidence suggest that changes in the
clearance of creatinine and Scr' might not reflect changes in
GFR as accurately as the renal clearance of radiolabeled
glomerular markers. First, fractional tubular creatinine secre-
tion was found to vary inversely with GFR in patients followed
longitudinally [41]. In patients whose GFR improved by about
33%, Shemesh et al found that changes in creatinine clearance
or Scr suggested only about a 13% improvement. Of 26
patients who underwent a remission (defined as an increase in
GFR and a decrease in albuminuria), serum creatinine did not
decline in 14, and only 13 of the 26 had an increase in creatinine
clearance. On the other hand, serum creatinine increased in all
but 3 of 28 patients with declining function, whereas creatinine
clearance declined in 22 of 28 patients. Thus, changes in
creatinine clearance and Scr' seemed to be more sensitive in
detecting a decline in GFR than in identifying an increase in
GFR. These results emphasize that variability between GFR
and serum creatinine is likely to be greatest in individuals with
modest reductions in GFR.
Second, Walser and coworkers compared changes in creati-
nine clearance and SCr' (corrected for an average value of
urinary creatinine) with the renal clearance of mtechnetium
diethylene triaminopentaacetic acid (99mTc..DTpA) in 17 pa-
tients with moderate to severe chronic renal failure (GFR, 4 to
23 mI/mm) [451. Over an average of 15 months, the slope of
creatinine clearance with time declined more rapidly and had
greater variance than did the renal clearance of 99mTcDTPA.
Although the authors concluded that 9 of 22 observations
revealed differing slopes between changes in creatinine and
99mTcDTPA clearances during all or part of the observation
period, the choice of periods analyzed is sensitive to observer
bias. Over the entire observation period, 4 of 22 observation
periods revealed different slopes for the two methods, and 3 of
those 4 periods suggested progression by creatinine clearance
when none was seen by 99mTc..DTpA In the remaining case,
the isotope clearance suggested improvement while creatinine
clearance remained stable. Interestingly, in 2 of 4 patients
whose slopes revealed stable 99mTcDTpA clearances but pro-
gression by creatinine clearance, dialysis was required; thus, in
those 2 patients, creatinine clearance was a better measure of
clinical outcome than was mTcDTPA clearance.
When rates of progression, as defined by changes in l/Scr,
were compared with mTcDTPA clearance, the variances
were similar, and the average slope for the groups did not differ;
6 of 22 slopes were statistically different between the two
methods when the entire observation period was analyzed. In
two instances, mTcDTPA renal clearance remained stable,
whereas SCr' declined. In two cases, both methods showed
progression (but the rate was statistically greater with the
method). In two instances each, Scr remained stable but
99rnTc..DTPA improved or decreased respectively. Thus, in only
4 of 22 patients would an inappropriate conclusion regarding
directional changes in renal function have been reached by
utilizing Scr. These data support the original proposal that
renal function can be monitored and is lost at a constant rate.
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Regardless, decisions about the effect of the diet on progression
require more than changes in serum creatinine concentration.
Fortunately, the Modification of Diet in Renal Disease (MDRD)
trial uses '251-iothalamate to measure GFR, and this practice
will avoid the problem in that study [47J.
After considering the variability in rates of progression
among individuals and the standard error of the slopes of their
regression lines, Walser concluded that at least four measure-
ments of GFR would be necessary to detect progression in most
patients and that little would be gained by requiring more than
five measurements [44]. Only the most rapid rates are detect-
able with just three measurements. Consequently, estimates of
progression based on two measurements (an initial and final
value) cannot establish progression rates in individuals unless
the fall in GFR greatly exceeds the error in GFR measurements.
Interestingly, as GFR declines, so does its error; hence, pro-
gression becomes easier to detect [20].
During the last 15 years, evidence has suggested that dietary
therapy can slow the progression of chronic renal failure. Many
of these studies have been criticized because of study design
(including the lack of randomization), retrospective analysis,
compliance issues, and/or the use of changes in the serum
creatinine or creatinine clearance to assess progression. Con-
sequently, conclusions regarding the efficacy of dietary protein
and/or phosphorus restriction on progression of chronic renal
failure in humans must be considered tentative.
Nonetheless, three nutritional regimens have been prescribed
to slow progression: (I) a conventional low-protein diet con-
taining 0.6 g protein/kg body weight/day of primarily high-
quality protein; (2) a very-low-protein diet supplemented with
essential amino acids; and (3) a very-low-protein diet supple-
mented with ketoacids.
The principal evidence that the use of unsupplemented,
low-protein diets can favorably influence the course of chronic
renal failure is derived from three reports [48—50], two of which
were randomized, prospective trials. In the earliest study,
Maschio et al in Verona compared the rates of progression in
three groups of patients [48]. Groups land!! were separated on
the basis of initial serum creatinine value, and each received a
diet containing 0.6 g/kg of predominantly high-quality protein,
40 kcal/kg energy intake, about 650 mg of phosphorus, and 1.0
to 1.5 g of calcium daily. The initial serum creatinine in Groups
1(25 patients), 11(20 patients), and III (30 patients) were 1.5 to
2.7 mgldl, 2.9 to 5.4 mg/dl, and 1.6 to 4.7 mg/dl, respectively.
Group III was a control population consuming an unrestricted
diet with average daily intakes of protein, phosphorus, and
calcium of 70 g, 900 mg, and 800 mg, respectively. Progression
was assessed by changes in serum creatinine or Scr. Groups
I and II had a far slower loss of renal function than did the
control group; the rate of decline was significantly slower in the
patients who began treatment at an earlier stage of disease.
The Verona group has periodically updated their experience.
In 1989 they reported on 390 patients treated with a low-protein
diet for 54 28 months: 57% of the patients had a stable serum
creatinine level, 11% had slower renal deterioration (defined as
an increase in Scr between 0.02 and 0.04 mgldllmonth and 32%
had rapid renal deterioration (greater than 0.04 mg/dl/month)
[51]. Individuals with milder renal disease seemed to have a
more favorable course, and patients with interstitial nephritis
fared better than did those with chronic glomerulonephritis or
polycystic kidney disease. Initial serum creatinine, proteinuria
on presentation, and systolic and diastolic blood pressures were
found to be independent prognostic factors. No adverse effects
of dietary therapy were noted, and indices of protein nutrition
were well maintained [48]. However, after an additional 5 years
of dietary restriction, the researchers noted significant loss of
muscle protein and a decrease in serum albumin and serum
transferrin concentrations (despite stable body weight and
indices of muscle mass) in a subgroup of 8 patients; this finding
suggests that ml' ;tional status tends to worsen after 5 or more
years [52]. Unfortunately, the energy intake of these 8 patients
was lower than that prescribed (26—29 kcal/kglday), so it is not
clear that dietary protein restriction alone causes protein wast-
ing.
In 1984, Rosman and coworkers reported the results of their
prospective randomized trial involving 149 patients followed for
at least 18 months (average of 24 months) after assignment to
low-protein or control diets [49]. The prescription depended on
the degree of renal insufficiency: 0.6 or 0.4 g/kg/day of protein
for patients with creatinine clearances between 30—60 mI/mm or
10—30 mI/mm, respectively. They concluded that a low-protein
diet significantly slowed the increase in serum creatinine, and
that patients under 40 years of age progressed more rapidly than
did older subjects. The authors noted no adverse influence of
protein restriction on nutritional status. These authors subse-
quently reported a 4-year followup of 153 of 248 patients
entering the study [53]. Although a significant benefit of dietary
protein restriction still was noted, it was most apparent in the
group with more advanced disease. In both the control and
low-protein diet groups, males showed a more rapid loss of
creatinine clearance but also seemed to respond to protein
restriction; females did not seem to benefit from dietary modi-
fication. Furthermore, slowing of disease progression was evi-
dent only in patients with glomerulonephritis. Disease progres-
sion in patients with polycystic kidney disease appeared to be
entirely related to blood pressure, whereas in the other diag-
nostic groups, variability in blood pressure did not correlate
with preservation of renal function. Finally, body weight and
serum proteins were stable over 36 months of dietary therapy,
but prescribing less than the minimum daily requirement of
protein to patients with a creatinine clearance less than 30
mI/mm could be hazardous nonetheless [17].
In Australia, IhIe et al compared a diet containing 0.4 g
protein/kg/day with an unrestricted protein intake in 64 subjects
who were followed for 18 months in a prospective, randomized
trial [50], The groups were initially well matched for blood
pressure, serum creatinine (range, 4.0 to 11.0 mgldl), and
calcium and phosphorus values. Changes in GFR were deter-
mined from the plasma disappearance of 51Cr-EDTA. End-
stage renal failure developed in 9 of 33 patients (27%) who
followed the unrestricted diet compared with only 2 of 31(6%)
who were compliant with the protein-restricted diet (P < 0.05);
the GFR decreased on average from about 15 mI/mm to 6
mI/mm in the former group, whereas it did not change signifi-
cantly in the protein-restricted group (from approximately 14
mI/mm to 12 mI/mm). The outcome of patients who did not
comply with the restricted diet was not detailed. Although
serum albumin and estimates of muscle mass remained stable
over the 18-month followup, weight, serum transferrin, and
total lymphocyte count decreased significantly. Because the
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phosphorus content of the protein-restricted diet was approxi-
mately 30% to 40% less than that of the unrestricted diet, the
relative importance of dietary protein versus phosphorus re-
striction on progression cannot be determined. The decline in
some, but not all, nutritional indices also raises concern about
prescribing less than the minimum daily requirement of protein
to patients with renal insufficiency. Clearly, we also need more
sensitive methods for assessing the nutritional adequacy of
currently recommended dietary regimens.
How did very-low-protein diets supplemented with essential
amino acids affect the progression of chronic renal failure?
Alvestrand and associates treated 17 patients who had well-
defined rates of decline of Scr' before beginning a regimen of
15—20 g of mixed-quality protein plus an EAA supplement
provided as tablets (containing 1.8 to 2.8 g nitrogen). The
patients were followed for an average of 355 days. Progression
was apparent even though many patients had been consuming a
diet restricted to 0.6 g protein/kg/day [24, 54]. Only 3 patients
did not show substantial slowing of progression. Interim reports
from an ongoing prospective, randomized trial by the same
group have cast doubt on what influence diet exerts on these
results and raises the possibility that better blood pressure
control and closer followup slowed progression of renal disease
[55]. Slowing of progression appeared to be related to a very
small, but significant, reduction in diastolic blood pressure (2
mm Hg); loss of function was greater in patients with protein-
uria. The relationship with blood pressure appears to exist at
levels well within the range considered "normal," so more
stringent blood pressure control than traditionally accepted
might exert a favorable effect on renal function. Although 57
patients were initially enrolled in the study, only 5 subjects in
the protein-restricted group and 9 in the control group satisfied
the requirements of the study. The authors concluded that rates
of progression before and after randomization did not differ, nor
could an effect of dietary protein restriction on progression be
discerned. Of note, the average intake of protein in the EAA-
treated group was higher than prescribed and although signifi-
cant, the difference from the intake of the unrestricted subjects
(0.65 g/kgiday versus 0.86 g/kg/day) was not striking.
In summary, an EAA regimen can be effective in controlling
the symptoms of chronic renal failure, but any benefit on
progression of disease remains uncertain. The major advantage
over a conventional low-protein diet is the greater variety of
foods, which might make the regimen more acceptable. It
appears to have little or no advantage in terms of improved
nitrogen conservation when compared with a conventional
low-protein diet.
Very-low-protein diets supplemented with ketoacids also
have been assessed. Barsotti and colleagues examined progres-
sion in 31 patients treated with a diet containing 0.5 g/kg of
high-quality protein and 600 mg of phosphorus/day; all showed
a linear decline in creatinine clearance despite dietary protein
restriction [56]. Twelve subjects were then treated for 10 to 15
months with approximately 0.2 g protein/kg/day, 300 mg/day of
phosphorus, plus a ketoacid-amino acid mixture. Eleven of the
12 had a marked decrease in the loss of creatinine clearance;
only one patient continued to lose renal function at the same
rate. The same group reported their experience with this
regimen in a larger number of patients whose renal insufficiency
progressed despite therapy with a conventional low-protein
unsupplemented diet. In patients compliant with the ketoacid
regimen, the decline in creatinine clearance was halted (0.1
0.12 mI/mm). Patients who were less compliant (average UNA,
6.3 gN/day) continued to lose renal function. We evaluated a
regimen containing 20 to 30 g of protein supplemented with a
mixture of the basic amino acid salts of ketoacids in 25 patients
[57]. Among 17 patients who demonstrated well-defined rates of
disease progression, 10 (59%) exhibited a significantly slower
rise in the serum creatinine level during long-term treatment
(average, 20 months). Seven of these 17 patients began treat-
ment before the serum creatinine reached 8 mg/dl; in 6, the
serum creatinine remained at or below the level at the start of
treatment. Thus, it appears that this regimen has a more
favorable influence if initiated relatively early in the course of
renal failure.
All these studies suggesting a beneficial effect of protein
and/or phosphorus restriction are based on creatinine measure-
ments, which can be unreliable estimates of progression. These
results also have not adequately compared a ketoacid-based
regimen with an EAA regimen or with a low-protein, unsupple-
mented diet. Walser and colleagues evaluated 12 patients given
a regimen containing 0.3 g protein/kg/day plus EAA; all had
progressive decline in creatinine clearance [58]. After the EAA
were changed to a ketoacid supplement, renal failure in all 6
patients whose serum creatinine level exceeded 7.5 mg/dl
continued to progress. In contrast, 6 of 7 patients whose serum
creatinine level was between 6.0 and 7.4 mg/dl at crossover had
stable values of GFR during the one- to two-year followup; one
patient who was noncompliant had to go on dialysis.
In summary, despite many provocative observations, it is not
established whether dietary protein and/or phosphorus restric-
tion can slow the progression of chronic renal failure or whether
a ketoacid-based regimen confers a therapeutic advantage. One
or more of the prospective, randomized multicenter trials now
in progress might answer these questions.
Let me conclude with a short comment on the progression of
renal disease in diabetic patients. A substantial proportion of
patients with insulin-dependent diabetes will develop renal
failure. Why some, but not all, patients are at risk is not known.
A genetic susceptibility to diabetic nephropathy might be im-
portant; diabetic siblings of patients with overt nephropathy are
more likely to have nephropathy, and black diabetic patients
have a higher incidence of end-stage renal disease when com-
pared with white patients. Hypertension can accelerate diabetic
nephropathy, and effective antihypertensive therapy reportedly
slows the decline in renal function [59].
Most investigators believe that microalbuminuria indicates a
high risk for the development of clinical diabetic nephropathy.
This observation is of interest because short-term dietary
protein restriction reduces protein losses in diabetic patients
with microalbuminuria [601.
Data on the efficacy of dietary protein restriction in slowing
progression of renal failure are limited. In a recent study of 19
insulin-dependent diabetic patients with persistent proteinuria,
conversion from an unrestricted diet (average, 1.13 g protein/
kg/day) to a diet averaging 0.67 g proteinlkg/day was associated
with a significant reduction in the rate of decline in GFR (from
0.61 to 0.14 mI/mm/month) [61]. Slowing of progression was
significant even after adjustments were made for differences in
blood pressure, energy intake, and glycosylated hemoglobin
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level. Albumin excretion and its fractional clearance also fell
with the low-protein diet. Another recent study found a similar
benefit of a low-protein diet on the progression of diabetic
nephropathy [62].
In summary, dietary protein restriction has been used by
many investigators to treat uremic symptoms. Our understand-
ing of the metabolic changes required to maintain nutrition and
to monitor compliance has increased rapidly. However, much
work is needed to define how uremia affects protein turnover
and how changes in lean body mass can be monitored most
effectively. Foods designed to be low in protein and phosphorus
are needed to improve compliance. Such knowledge will be
especially useful if results from prospective clinical trials
strengthen the results of the reports reviewed.
Questions and answers
DR. NIcoLAos E. MADIAS (Chief, Division of Nephrology,
New England Medical Center, Boston, Massachusetts): You
stated that a decrease in protein intake in the company of
ketoacid supplementation can improve renal osteodystrophy on
the basis of decreasing the level of PTH and increasing the
concentration of 1,25 dihydroxycholecalciferol. Is there any
evidence derived by direct or indirect methods that the severity
of renal osteodystrophy is indeed lessened by utilization of such
a dietary regimen?
DR. MITCH: Data from Germany suggest that a low-protein,
low-phosphorus diet plus calcium ketoacids is associated with a
reduction in the level of parathyroid hormone in the blood [631.
Maschio and colleagues showed that patients fed 0.6 g protein!
kg/day had stabilization of the histology of bone on bone biopsy
[64]. I don't know of a study of bone biopsy in patients given
ketoacids.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton-
Wellesley Hospital, Newton, Massachusetts): You mentioned
that a decreased dietary protein intake decreases amino acid
oxidation. What is the link between those two steps?
Da. MITCH: I don't think anybody knows. One possibility is
that the low-protein diet reduces glucocorticoids because glu-
cocorticoids influence the activity of the enzyme that breaks
down the essential, branched-chain amino acids [65].
DR. ANDREW S. LEVEY (Division of Nephrology, New En-
gland Medical Center): I'd like to return to data from the study
by IhIe et a! [50]. These investigators demonstrated a lower rate
of loss of renal function in patients with moderately severe renal
insufficiency (mean GFR, 25 mI/mm/I .73 m2) treated with a
low-protein diet. It was interesting to note that protein intake
estimated from urinary urea excretion was 0.7—0.8 g/kg/day in
the low-protein-diet group and 0.9—1.0 g/kg/day in the unre-
stricted-protein-diet group. Thus the dietary intervention ap-
peared to be only a relatively small reduction in protein intake,
and the level of protein intake that was achieved was a level that
is customary in many parts of the world. Would you comment
on the "dose-response" relationship between the level of
protein intake and the proposed beneficial effect on delaying the
progression of renal disease?
DR. MITCH: Interestingly, the protein intake slowing progres-
sion in diabetic patients also was approximately 0.7 glkg/day.
Perhaps a response could be achieved without marked dietary
restriction, or it might be that the response is graded, or that
patients with certain types of disease won't respond. The
patient discussed had inherited nephropathy, yet apparently she
responded. Barsotti suggested that the ketoacid regimen slows
the decline in creatinine clearance experienced by patients with
polycystic disease [66].
DR. MAmAs: Regarding your data in rats showing that
metabolic acidosis accelerates protein catabolism, have studies
in humans with chronic renal failure related protein degradation
to the prevailing degree of acidemia? Have any formal studies
examined this issue in adults with renal tubular acidosis?
DR. MITCH: I know of 3 studies showing that correcting the
plasma bicarbonate improved nitrogen balance in patients with
chronic renal failure [67—69]. Children with inherited renal
tubular acidosis have improved growth when they are given
sodium bicarbonate [70]. Finally, Bergstrom and associates
recently showed that the blood bicarbonate level in dialysis
patients correlates directly with the valine concentration in
muscle; hence, acidosis likely stimulates valine catabolism and
limits protein utilization [23].
DR. MADIAS: Has the effect of respiratory acidosis on protein
metabolism been examined?
DR. MITCH: Not to my knowledge.
DR. PAUL KURTIN (Director, Dialysis Unit, New England
MedicalCenter): In contrast to your studies and those of others
you quoted [33, 34], growing infants can incorporate exogenous
urea into non-essential amino acids. In addition, we have
observed that adults in acute renal failure given parenteral
essential amino acids and adequate calories can have a fall in
BUN [71]. This finding suggests the incorporation of endoge-
nous urea into non-essential amino acids and protein anabolism.
Would you please comment on this? Second, would you com-
ment on the studies by Bonomini, which suggest that the longer
a patient is on a low-protein diet, the worse the results of
anemia and nerve conduction studies after dialysis is started
[72].
DR. MITCH: Not only in infants but also in malnourished
adults can urea improve nitrogen balance [73]. On the other
hand, in adult patients with chronic renal failure fed an ade-
quate amount of calories, we find no evidence that urea
nitrogren is utilized to synthesize amino acids. In patients with
acute renal failure, the lower nitrogen intake occurring with
feeding essential amino acids could reduce urea production and
hence the BUN. Regarding the initiation of dialysis, the deci-
sion generally is based on clinical criteria, and if patients do not
have uremic symptoms, dialysis is not necessary.
DR. KURTIN: I interpreted Bonomini's studies as showing
that if patients are started on dialysis based on a pre-determined
BUN, and if they are on a low-protein diet, it will take longer
for these patients to reach the target BUN, while other compo-
nents of the uremic syndrome can progress.
DR. MITCH: 1 suspect we need careful studies to examine
whether dialysis benefits these patients.
DR. MADIAS: To what extent should the recommendations
for protein restriction in chronic renal failure be changed as a
function of age, that is, for children, adults, and the elderly?
Also, what about patients who are on high-dose steroid treat-
ment?
DR. MITCH: You asked two important questions. Nobody has
studied requirements as a function of the age of uremic patients.
Patients given high doses of glucocorticoids, and patients with
the nephrotic syndrome also remain a mystery, at least regard-
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ing their protein requirement. Studies of the safety of low-
protein diets in severely nephrotic patients and/or patients
taking glucocorticoids are needed because this is an important
clinical problem.
DR. MADIAS: Should one modify the dietary recommenda-
tions during periods of stress (for example, intercurrent illness)
as one does for non-uremic subjects?
DR. MITCH: That approach appears rational as long as the
extra protein does not cause uremic symptoms.
DR. HARRINGTON: I remain a skeptic about the effect of a low
protein intake. I would argue that the most important thing you
did was control the patient's blood pressure. Both experimen-
tally and clinically, in say accelerated hypertension and in
diabetes, I believe that control of blood pressure is paramount.
In the studies that have been done about the efficacy of a low
protein intake, has the role of control of hypertension been
taken into account? I can't imagine that any nephrologist would
leave patients with blood pressures of 222/120 mm Hg merely to
carry out the rigorous study that I want.
DR. MITCH: The definitive study hasn't been done because
blood pressure is always treated. However, controlling blood
pressure alone seems to have the most benefit in slowing
progression to renal failure in patients with accelerated hyper-
tension.
DR. LEVEY: In the study by Ihle et al, patients in the
low-protein-diet group lost 2—4 kg in weight on average during
the first few months of followup. In my experience, this is a
common finding in patients who follow a low-protein diet. Has
anyone carefully studied such patients to determine whether
weight loss is the result of loss of body fat, salt, or muscle?
DR. MITCH: In the patients we treated for many months with
a very-low-protein diet, we found no significant change in
weight on average [32, 57]. Some patients did lose weight, but
we did not examine whether there was loss of bone, fluid, or
muscle and fat. Lucas et al prescribed half the amount of
ketoacids and less than half the amount of protein as others use,
so those results should not be extrapolated to other patients
treated with ketoacids [191.
DR. MADIAS: In your view, what is the importance of changes
in insulin and glucagon levels for the abnormalities in interme-
diary metabolism in uremia?
DR. MITCH: We found that uremia is associated with resis-
tance to insulin in terms of protein metabolism [74]. The
importance of glucagon and other hormones in impairing pro-
tein metabolism in uremia is less certain [20].
DR. HARRINGTON: What is the impact of gender on progres-
sion of renal disease? I ask because Lombet et al have reported
that renal insufficiency in the ¾ nephrectomized female rat
didn't progress at the same rate as in male rats [75].
DR. MITCH: Some studies suggest that women respond to a
low-protein diet, but the question has not been examined in
detail [49, 53].
DR. RONALD PERRONE (Division of Nephrology, New En-
gland Medical Center): When you first place an ambulatory
patient on a low-protein diet and measure the estimated protein
intake using urea nitrogen, how do you distinguish the non-
compliant patient from the patient in negative nitrogen balance?
At what point are you able to rely on the urinary urea nitrogen
as an indicator of compliance?
DR. MITCH: You raise critically important issues. As long as
the BUN and weight are changing (weight being an index of
total body water), then urea excretion cannot be used to
estimate protein intake. If the BUN and weight are stable and
urea nitrogen excretion is consistently higher than the amount
of dietary protein nitrogen prescribed, then only two possibili-
ties exist: (1) the patient is eating too much, or (2) the patient is
catabolic or has gastrointestinal bleeding. Distinguishing be-
tween the possibilities requires careful examination and evalu-
ation by a dietician. Finally, the test should be repeated.
DR. PERRONE: Are there any specific parameters of catabo-
lism that you would follow up?
DR. MITCH: During long-term therapy, body weight, serum
albumin, and transferrin seem to be reliable. We believe the
serum bicarbonate should be kept above 22 mM.
DR. BRIAN PEREIRA (Fellow, Division of Nephrology, New
England Medical Center): What would you consider early
enough, as far as dietary intervention is concerned? My second
question relates to protein restriction in acute renal failure. Has
anyone studied whether intervention has any effect on the
speed or completeness of recovery in acute renal failure?
DR. MITCH: These data do not prove protein restriction slows
progression even though the diet will reduce symptoms. If a
patient has a rising serum creatinine and a high BUN, then a
low-protein diet should be considered. Regarding low-protein
diets in acute renal failure, attempts to show improved survival
from acute renal failure with different types of amino acids or
low-protein regimens have not proved that survival improves
[76]. I believe that we need a method of limiting catabolism
stimulated by other illnesses or renal failure itself. We can
replace renal function, but until catabolism can be controlled, it
seems unlikely that survival time will improve.
DR. HARRINGTON: How much time does it take for the
nutritionist to teach a new patient about a 0.6 g/kg intake, and
how often do patients have to see the nutritionist? Please try to
be as quantitative as possible in your answers.
DR. MITCH: That depends on the intelligence of the patient
and his or her commitment plus the skill of the dietician.
Dieticians in the MDRD study spend quite a bit of time
educating these patients, but in our studies the dietician meets
with the patient during the initial hospitalization in the clinical
research center and monthly thereafter. Each visit lasts 30 to 45
minutes. After about 6 to 8 months, many patients are seen
every other month, and we calculate that they are compliant
based on urea excretion and body weight [1].
DR. KURTIN: In healthy individuals, as total protein intake
falls, energy intake must increase to maintain nitrogen balance.
Do you maintain your patients on diets of 35 kcal/kg? What
caloric intake do you recommend for the very-low-protein
diets?
DR. MITCH: It is difficult to maintain a low-protein diet and a
high-calorie diet without using supplements of carbohydrate
polymers. This supplement is not too sweet and will increase
calories. However, we often do not achieve the desired 35
kcal/kg.
DR. GEETHA NARAYAN (Nephrologist, St. Elizabeth's Hos-
pital, Brighton, Massachusetts): In developing countries like
India, renal disease requiring dialysis seems to be just as
prevalent in lower socioeconomic groups as in higher despite
the fact that these people often consume diets very low in
protein, even bordering on protein calorie malnutrition at times.
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Hence, at least in these populations, other factors seem to
override the effects of a low-protein diet. Would you comment
on this, and are any data available on protein intake in these
patients?
DR. MITCH: You raise an interesting point. Perhaps patients
in underdeveloped countries don't see a physician until they
have advanced uremia, and they can have secondary illnesses.
The patient discussed today had loss of renal function each time
she had a bout of diarrhea and fever. Fortunately, she recov-
ered. We concluded that an infection along with diarrhea or
fever can impair renal function acutely. If other illnesses
complicate renal failure in a patient from a third world country,
the patient might not receive medical care until renal failure is
quite advanced.
DR. MADIAS: What might be the implications of a protein-
restricted diet and the provision of adequate energy from
nonprotein sources on the lipid abnormalities of uremia?
DR. MITCH: This question hasn't been examined carefully in
predialysis patients. In patients we have treated, hypertriglyc-
eridemia often is present, but an elevated total cholesterol is
unusual.
DR. LEVEY: Would you speculate on the mechanism of the
proposed beneficial effect of low-protein diets and essential
ketoacid supplements in retarding the progression of renal
disease?
DR. MITCH: If the diet works in patients with inherited renal
disease and in patients with diabetes and/or other types of
diseases, a common factor probably is present in all patients.
Such a factor has not been identified. In the patients we treated,
I have tried unsuccessfully to find a correlation between mean
blood pressure, systolic or diastolic pressure, and rates of
progression. Regarding ketoacids, I don't know whether there
is a special effect; they might permit a lower protein intake.
Barsotti and associates followed patients whose renal disease
progressed while they ate 0.6 g protein/kg/day, but this progres-
sion stopped when the patients began the ketoacid regimen [56].
DR. LEVEY: I agree that the published data comparing rates
of decline in GFR (measured as clearance of radioisotope-
labeled filtration markers), creatinine clearance, and reciprocal
serum creatinine are scarce, and that until it is determined that
these latter measures correlate closely with the rate of decline
in GFR, it is important that we include measurements of GFR in
studies of the effect of interventions on the course of progres-
sive renal disease. I do not agree, however, with the suggestion
that an apparent linear decline in the rate of decline in renal
function, measured as either GFR, creatinine clearance, or
reciprocal serum creatinine, justifies using the patients as their
own "controls" in such studies, rather than using a concurrent
control group that does not receive the intervention. Interpre-
tation of changes in the rate of decline in individual patients
requires assessment of 4 things: (1) carry-over effects from the
previous interval; (2) effects of factors other than the interven-
tion that could influence renal function; (3) regression to the
mean [47], and (4) spontaneous breakpoints [47]. In principle, it
is possible to assess these effects only if a concurrent control
group is studied or if the experimental group is studied on both
diets in a crossover design in random order.
DR. HARRINGTON: I have a question for Dr. Levey. The
MDRD Study has been going on for a few years. What is the
latest information from that important study?
DR. LEVEY: Two groups of patients are being evaluated in the
MDRD study; one group has GFRs of 25—55 mI/mm/I .73 m2
(Study A), and the other has GFRs of 13—24 ml/min/l.73 m2
(Study B). The patients in Study B have renal function compa-
rable to that in the patients studied by IhIe et al in Australia. As
of the end of 1990, we have randomized 200 patients into Study
B, which compares a diet containing 0.575 g/kg/day protein with
a diet containing 0.28 g/kg/day protein supplemented with
essential keto acids. This study should enable us to determine
whether there are different effects of different low-protein diets
in patients with severe impairment in renal function. In addi-
tion, in each diet group we are comparing two levels of blood
pressure: a usual blood pressure goal of MAP (mean arterial
pressure)  107 mm Hg (equivalent to  140/90 mm Hg) and a
low blood pressure goal of MAP 92 mm Hg (equivalent to 
127/75 mm Hg). Hopefully this strategy will enable us to
determine whether the level of arterial blood pressure affects
the progression of renal disease. In Study A, we have random-
ized approximately 400 patients to one of two diet groups, a
usual-protein diet containing 1.3 g/kg/day versus a low-protein
diet containing 0.575 glkg/day. Patients in each group also are
randomized to either the usual or low blood pressure goal. This
study will test the effectiveness of a low-protein diet and
lower-than-usual level of blood pressure in patients with mild to
moderate impairment in renal function. After completion of
enrollment, the planned duration of followup is approximately 2
years.
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